benzatropine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
atropine derivatives	333	86-13-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cogentin benztropine mesilate benzatropine benztropine tropine benzohydryl ether benztropine mesylate	A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine. Molecular weight: 307.44 Formula: C21H25NO CLOGP: 3.52 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 12.47 ALOGS: -5.41 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cogentin
benztropine mesilate
benzatropine
benztropine
tropine benzohydryl ether
benztropine mesylate

A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.

Molecular weight: 307.44
Formula: C21H25NO
CLOGP: 3.52
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 12.47
ALOGS: -5.41
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	mg	O
2	mg	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.21 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	29 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
March 5, 1954	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	401.57	20.67	242	7831	145431	63335518
Toxicity to various agents	172.22	20.67	183	7890	247067	63233882
Psychotic disorder	151.10	20.67	71	8002	25641	63455308
Tardive dyskinesia	146.78	20.67	51	8022	8451	63472498
Granulocytopenia	146.00	20.67	46	8027	5626	63475323
Schizophrenia	142.65	20.67	52	8021	9900	63471049
Hallucination, auditory	96.18	20.67	42	8031	12782	63468167
Oculogyric crisis	88.99	20.67	24	8049	1697	63479252
Neuroleptic malignant syndrome	88.84	20.67	39	8034	12017	63468932
Paranoia	80.33	20.67	36	8037	11643	63469306
Akathisia	75.29	20.67	32	8041	9114	63471835
Muscle rigidity	71.37	20.67	33	8040	11467	63469482
Extrapyramidal disorder	69.83	20.67	34	8039	13250	63467699
Agitation	65.61	20.67	57	8016	59700	63421249
Sedation	61.73	20.67	46	8027	38763	63442186
Cardiac arrest	59.75	20.67	66	8007	92479	63388470
Catatonia	59.00	20.67	22	8051	4455	63476494
Dyskinesia	57.87	20.67	41	8032	31961	63448988
Clonus	54.65	20.67	21	8052	4615	63476334
Drooling	54.62	20.67	20	8053	3848	63477101
Myocarditis	52.98	20.67	26	8047	10299	63470650
Haemoglobin urine	52.65	20.67	10	8063	140	63480809
Drug interaction	51.53	20.67	99	7974	229032	63251917
Hyperreflexia	49.63	20.67	21	8052	5913	63475036
Ileus paralytic	47.94	20.67	19	8054	4532	63476417
Salivary hypersecretion	47.57	20.67	22	8051	7644	63473305
Tremor	46.83	20.67	70	8003	132169	63348780
Encephalitis autoimmune	46.48	20.67	14	8059	1472	63479477
Suicidal ideation	46.42	20.67	48	8025	62373	63418576
Dystonia	45.85	20.67	26	8047	13793	63467156
Schizoaffective disorder	45.10	20.67	17	8056	3545	63477404
Electrocardiogram QT prolonged	42.87	20.67	45	8028	59485	63421464
Abnormal behaviour	42.35	20.67	29	8044	21397	63459552
Hyperthermia	40.93	20.67	21	8052	9135	63471814
Postmortem blood drug level	40.72	20.67	8	8065	135	63480814
Red blood cells urine	39.44	20.67	10	8063	555	63480394
Eosinophil count abnormal	39.04	20.67	10	8063	578	63480371
Amaurosis	38.69	20.67	10	8063	599	63480350
Delusion	38.23	20.67	22	8051	11995	63468954
Treatment noncompliance	37.75	20.67	34	8039	37291	63443658
Death	34.32	20.67	115	7958	374266	63106683
Cardio-respiratory arrest	33.99	20.67	40	8033	59919	63421030
Antidepressant drug level above therapeutic	31.82	20.67	8	8065	429	63480520
Blood prolactin increased	31.31	20.67	13	8060	3490	63477459
Aggression	31.13	20.67	25	8048	23473	63457476
Psychiatric decompensation	30.46	20.67	10	8063	1391	63479558
Somnolence	29.39	20.67	68	8005	178617	63302332
Impulsive behaviour	29.26	20.67	10	8063	1573	63479376
Suspected suicide	29.17	20.67	15	8058	6553	63474396
Torsade de pointes	28.61	20.67	19	8054	13332	63467617
Arthralgia	26.87	20.67	20	8053	569690	62911259
Mental status changes	26.85	20.67	29	8044	39570	63441379
Food interaction	26.66	20.67	8	8065	830	63480119
Confusional state	26.58	20.67	78	7995	236302	63244647
Toxic encephalopathy	26.29	20.67	14	8059	6565	63474384
Restlessness	26.23	20.67	25	8048	29428	63451521
Mania	25.06	20.67	17	8056	12350	63468599
Pain	24.75	20.67	35	8038	740593	62740356
Pneumonia aspiration	24.66	20.67	26	8047	34514	63446435
Labelled drug-drug interaction issue	24.51	20.67	8	8065	1093	63479856
Grandiosity	24.39	20.67	6	8067	294	63480655
Hallucination	23.78	20.67	32	8041	54785	63426164
Mydriasis	23.19	20.67	16	8057	11940	63469009
Schizoaffective disorder bipolar type	23.14	20.67	5	8068	137	63480812
Facial paralysis	23.11	20.67	17	8056	14024	63466925
Mental impairment	22.99	20.67	17	8056	14134	63466815
Areflexia	22.68	20.67	10	8063	3108	63477841
Flat affect	22.35	20.67	8	8065	1442	63479507
Dysarthria	21.76	20.67	27	8046	42684	63438265
Unresponsive to stimuli	21.59	20.67	24	8049	33792	63447157

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	247.31	20.48	211	9628	97957	34849135
Granulocytopenia	201.16	20.48	74	9765	6493	34940599
Myocarditis	182.21	20.48	85	9754	13597	34933495
Toxicity to various agents	148.42	20.48	228	9611	200134	34746958
Tardive dyskinesia	147.40	20.48	57	9782	5733	34941359
Neuroleptic malignant syndrome	127.30	20.48	73	9766	17861	34929231
Cogwheel rigidity	110.25	20.48	32	9807	1320	34945772
Schizophrenia	106.61	20.48	51	9788	8615	34938477
Extrapyramidal disorder	101.06	20.48	56	9783	12824	34934268
Dystonia	92.97	20.48	50	9789	10795	34936297
Anticholinergic syndrome	85.87	20.48	26	9813	1243	34945849
Psychotic disorder	83.54	20.48	63	9776	24389	34922703
Hallucination, auditory	80.53	20.48	47	9792	11870	34935222
Head titubation	78.06	20.48	19	9820	392	34946700
Tremor	76.91	20.48	105	9734	82482	34864610
Agitation	70.87	20.48	84	9755	57315	34889777
Hyperprolactinaemia	68.00	20.48	23	9816	1573	34945519
Drug interaction	66.38	20.48	175	9664	225771	34721321
Sedation	64.91	20.48	51	9788	20955	34926137
Treatment noncompliance	61.64	20.48	56	9783	28044	34919048
Akathisia	60.17	20.48	34	9805	8075	34939017
Drug abuse	54.56	20.48	99	9740	98997	34848095
Galactorrhoea	52.01	20.48	14	9825	436	34946656
Drooling	51.23	20.48	23	9816	3359	34943733
Sinus tachycardia	51.17	20.48	41	9798	17319	34929773
Device leakage	49.95	20.48	28	9811	6547	34940545
Muscle rigidity	49.58	20.48	33	9806	10485	34936607
Product dose omission issue	47.16	20.48	104	9735	119607	34827485
Blood creatine phosphokinase increased	44.70	20.48	59	9780	44798	34902294
Abnormal behaviour	43.81	20.48	44	9795	24925	34922167
Parkinsonism	41.93	20.48	27	9812	8111	34938981
Restlessness	41.25	20.48	43	9796	25439	34921653
Sedation complication	39.96	20.48	16	9823	1761	34945331
Delusion	39.72	20.48	31	9808	12604	34934488
Delirium	39.49	20.48	55	9784	43936	34903156
Syringe issue	37.36	20.48	22	9817	5642	34941450
Priapism	37.21	20.48	21	9818	4973	34942119
Schizoaffective disorder	37.12	20.48	14	9825	1313	34945779
Dyskinesia	36.60	20.48	38	9801	22375	34924717
Serotonin syndrome	36.58	20.48	36	9803	19897	34927195
Mental status changes	34.75	20.48	48	9791	38035	34909057
Cerebral amyloid angiopathy	34.44	20.48	8	9831	134	34946958
Catatonia	34.41	20.48	20	9819	5005	34942087
Eosinophilic pleural effusion	33.98	20.48	9	9830	263	34946829
Aggression	33.90	20.48	48	9791	38916	34908176
Troponin increased	33.77	20.48	27	9812	11362	34935730
Dystonic tremor	30.99	20.48	8	9831	211	34946881
Antipsychotic drug level increased	30.83	20.48	17	9822	3848	34943244
Drug level increased	30.02	20.48	34	9805	22062	34925030
Rhabdomyolysis	30.00	20.48	62	9777	68101	34878991
Pericarditis	29.10	20.48	25	9814	11620	34935472
Inappropriate schedule of product administration	29.00	20.48	58	9781	62238	34884854
Blood prolactin increased	26.75	20.48	12	9827	1748	34945344
Hallucination	26.47	20.48	50	9789	51448	34895644
Blood pH decreased	26.47	20.48	13	9826	2321	34944771
Paranoia	26.34	20.48	24	9815	12044	34935048
Parasomnia	26.15	20.48	8	9831	396	34946696
Needle issue	25.86	20.48	18	9821	6147	34940945
Antipsychotic drug level decreased	25.83	20.48	10	9829	1007	34946085
Echocardiogram abnormal	25.40	20.48	10	9829	1053	34946039
Haemophagocytic lymphohistiocytosis	24.86	20.48	24	9815	12949	34934143
Tri-iodothyronine decreased	24.82	20.48	6	9833	120	34946972
Oculogyric crisis	24.70	20.48	11	9828	1575	34945517
Non-high-density lipoprotein cholesterol increased	24.11	20.48	6	9833	136	34946956
Gynaecomastia	23.71	20.48	21	9818	10159	34936933
Device malfunction	23.29	20.48	21	9818	10400	34936692
Unmasking of previously unidentified disease	23.26	20.48	9	9830	905	34946187
Agranulocytosis	23.20	20.48	31	9808	23790	34923302
Diarrhoea	23.09	20.48	47	9792	389865	34557227
Somnolence	22.86	20.48	76	9763	111040	34836052
Lethargy	22.48	20.48	41	9798	41081	34906011
Globulins increased	22.03	20.48	7	9832	393	34946699
Thyroxine decreased	21.53	20.48	6	9833	213	34946879
Globulins decreased	21.51	20.48	6	9833	214	34946878
Febrile neutropenia	21.42	20.48	6	9833	136843	34810249
Oedema peripheral	21.24	20.48	4	9835	119808	34827284
Faecaloma	20.93	20.48	15	9824	5362	34941730
Mania	20.93	20.48	19	9820	9492	34937600
Antipsychotic drug level above therapeutic	20.65	20.48	9	9830	1224	34945868
Muscle contracture	20.57	20.48	9	9830	1235	34945857
Disease progression	20.51	20.48	3	9836	108074	34839018

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	663.36	19.39	466	14518	245301	79484103
Granulocytopenia	357.33	19.39	118	14866	11313	79718091
Toxicity to various agents	299.73	19.39	381	14603	421159	79308245
Tardive dyskinesia	263.13	19.39	92	14892	10479	79718925
Myocarditis	214.64	19.39	97	14887	21636	79707768
Neuroleptic malignant syndrome	198.59	19.39	99	14885	27460	79701944
Schizophrenia	185.14	19.39	79	14905	15361	79714043
Psychotic disorder	171.16	19.39	103	14881	41299	79688105
Agitation	133.25	19.39	126	14858	99589	79629815
Hallucination, auditory	130.61	19.39	68	14916	20625	79708779
Drug interaction	115.48	19.39	246	14738	414937	79314467
Dystonia	111.74	19.39	62	14922	21337	79708067
Tremor	108.19	19.39	146	14838	169937	79559467
Extrapyramidal disorder	100.41	19.39	59	14925	22620	79706784
Muscle rigidity	99.44	19.39	56	14928	19826	79709578
Oculogyric crisis	94.31	19.39	31	14953	2921	79726483
Sedation	87.90	19.39	75	14909	51820	79677584
Catatonia	86.15	19.39	39	14945	8717	79720687
Treatment noncompliance	85.40	19.39	74	14910	52194	79677210
Cogwheel rigidity	81.15	19.39	28	14956	3060	79726344
Akathisia	79.19	19.39	42	14942	13217	79716187
Schizoaffective disorder	74.43	19.39	24	14960	2128	79727276
Paranoia	74.26	19.39	46	14938	19386	79710018
Device leakage	72.31	19.39	37	14947	10819	79718585
Drooling	69.91	19.39	30	14954	5904	79723500
Drug abuse	69.51	19.39	116	14868	162575	79566829
Dyskinesia	68.35	19.39	61	14923	44712	79684692
Delusion	67.22	19.39	44	14940	20379	79709025
Salivary hypersecretion	60.33	19.39	36	14948	14188	79715216
Product dose omission issue	59.97	19.39	139	14845	247398	79482006
Hyperprolactinaemia	59.61	19.39	25	14959	4651	79724753
Mental status changes	57.74	19.39	67	14917	66892	79662512
Aggression	56.13	19.39	58	14926	50900	79678504
Arthralgia	55.79	19.39	19	14965	571784	79157620
Syringe issue	55.54	19.39	26	14958	6272	79723132
Parkinsonism	55.24	19.39	36	14948	16548	79712856
Hallucination	55.04	19.39	74	14910	85671	79643733
Galactorrhoea	55.02	19.39	22	14962	3624	79725780
Restlessness	55.00	19.39	55	14929	46437	79682967
Abnormal behaviour	54.36	19.39	49	14935	36372	79693032
Death	53.38	19.39	229	14755	566285	79163119
Ileus paralytic	53.32	19.39	29	14955	9591	79719813
Anticholinergic syndrome	51.77	19.39	21	14963	3590	79725814
Blood creatine phosphokinase increased	50.19	19.39	62	14922	66028	79663376
Sinus tachycardia	49.93	19.39	47	14937	36861	79692543
Haemoglobin urine	47.92	19.39	10	14974	153	79729251
Cardio-respiratory arrest	47.15	19.39	78	14906	108432	79620972
Hyperreflexia	45.70	19.39	25	14959	8360	79721044
Pain	42.35	19.39	42	14942	703760	79025644
Diarrhoea	41.97	19.39	63	14921	880426	78848978
Clonus	41.78	19.39	22	14962	6818	79722586
Antipsychotic drug level increased	41.70	19.39	21	14963	5936	79723468
Priapism	40.97	19.39	19	14965	4486	79724918
Mania	40.69	19.39	31	14953	18229	79711175
Eosinophilic pleural effusion	40.63	19.39	10	14974	329	79729075
Intentional overdose	40.55	19.39	72	14912	105888	79623516
Joint swelling	39.89	19.39	4	14980	288642	79440762
Blood prolactin increased	39.88	19.39	18	14966	3993	79725411
Rhabdomyolysis	39.37	19.39	70	14914	103061	79626343
Head titubation	38.83	19.39	12	14972	926	79728478
Encephalitis autoimmune	38.68	19.39	15	14969	2279	79727125
Device malfunction	38.36	19.39	32	14952	21416	79707988
Anaemia	38.12	19.39	18	14966	444997	79284407
Needle issue	37.83	19.39	26	14958	13042	79716362
Suicidal ideation	37.44	19.39	58	14926	76282	79653122
Delirium	36.98	19.39	61	14923	84566	79644838
Gynaecomastia	36.69	19.39	21	14963	7660	79721744
Antipsychotic drug level above therapeutic	36.50	19.39	14	14970	2066	79727338
Somnolence	35.42	19.39	112	14872	238869	79490535
Suspected suicide	35.32	19.39	23	14961	10553	79718851
Cardiac arrest	34.57	19.39	90	14894	172006	79557398
Dystonic tremor	34.20	19.39	8	14976	211	79729193
Dysarthria	34.03	19.39	52	14932	67570	79661834
Red blood cells urine	33.26	19.39	10	14974	703	79728701
Eosinophil count abnormal	32.75	19.39	10	14974	741	79728663
Confusional state	32.55	19.39	132	14852	317865	79411539
Inappropriate schedule of product administration	32.26	19.39	75	14909	133553	79595851
Respiratory arrest	31.46	19.39	46	14938	57504	79671900
Psychiatric decompensation	30.80	19.39	15	14969	3948	79725456
Persecutory delusion	30.58	19.39	16	14968	4893	79724511
Cerebral amyloid angiopathy	30.55	19.39	8	14976	339	79729065
Tachycardia	29.78	19.39	87	14897	177681	79551723
Drug level increased	29.78	19.39	37	14947	39614	79689790
Agranulocytosis	29.09	19.39	39	14945	44991	79684413
Amaurosis	28.22	19.39	10	14974	1181	79728223
Electroconvulsive therapy	28.21	19.39	6	14978	101	79729303
Unresponsive to stimuli	28.21	19.39	43	14941	55745	79673659
Parasomnia	26.74	19.39	8	14976	553	79728851
Leukopenia	26.61	19.39	64	14920	116449	79612955
White blood cell count increased	26.37	19.39	49	14935	74584	79654820
Overdose	26.07	19.39	85	14899	184121	79545283
Postmortem blood drug level	25.78	19.39	7	14977	341	79729063
Mental impairment	25.28	19.39	24	14960	19012	79710392
Fatigue	25.25	19.39	90	14894	929637	78799767
Oedema peripheral	25.22	19.39	8	14976	252280	79477124
Hypersensitivity	23.38	19.39	10	14974	262229	79467175
Dyspnoea	23.23	19.39	83	14901	856942	78872462
Electrocardiogram QT prolonged	23.21	19.39	52	14932	90334	79639070
Autonomic nervous system imbalance	23.03	19.39	13	14971	4617	79724787
Neutrophil count increased	22.99	19.39	28	14956	29368	79700036
Mydriasis	22.96	19.39	22	14962	17621	79711783
Haemophagocytic lymphohistiocytosis	22.51	19.39	24	14960	21813	79707591
Disease progression	22.04	19.39	4	14980	184358	79545046
Alopecia	21.97	19.39	8	14976	231347	79498057
Muscle contracture	21.78	19.39	10	14974	2307	79727097
Mental disorder	21.59	19.39	28	14956	31274	79698130
Non-high-density lipoprotein cholesterol increased	21.30	19.39	6	14978	335	79729069
Antidepressant drug level above therapeutic	21.19	19.39	7	14977	669	79728735
Gait disturbance	21.09	19.39	86	14898	207420	79521984
Clang associations	21.02	19.39	4	14980	37	79729367
Headache	20.71	19.39	59	14925	653713	79075691
Hyperthermia	20.70	19.39	21	14963	18016	79711388
Antipsychotic drug level below therapeutic	20.54	19.39	8	14976	1230	79728174
Febrile neutropenia	20.28	19.39	9	14975	230990	79498414
Blood pH decreased	20.17	19.39	12	14972	4699	79724705
Pneumonia aspiration	20.04	19.39	41	14943	66926	79662478
Peripheral swelling	20.03	19.39	13	14971	269604	79459800
Swelling	19.74	19.39	8	14976	216703	79512701
Unmasking of previously unidentified disease	19.72	19.39	9	14975	2048	79727356
Troponin increased	19.56	19.39	21	14963	19234	79710170
Neutropenia	19.52	19.39	106	14878	287604	79441800
Disorganised speech	19.47	19.39	9	14975	2108	79727296
General physical health deterioration	19.47	19.39	14	14970	275224	79454180
Nephrogenic diabetes insipidus	19.40	19.39	9	14975	2125	79727279
Pain in extremity	19.39	19.39	24	14960	364514	79364890

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N04AC01	NERVOUS SYSTEM ANTI-PARKINSON DRUGS ANTICHOLINERGIC AGENTS Ethers of tropine or tropine derivatives
FDA MoA	N0000000207	Histamine Receptor Antagonists
FDA MoA	N0000175370	Cholinergic Antagonists
FDA EPC	N0000175574	Anticholinergic
CHEBI has role	CHEBI:48407	antiparkinson agent
CHEBI has role	CHEBI:48876	muscarinic antagonists
CHEBI has role	CHEBI:50370	parasympatholytics
CHEBI has role	CHEBI:66956	antidyskinetic agent
CHEBI has role	CHEBI:146270	oneirogens
CHEBI has role	CHEBI:149553	anticoronaviral drug
MeSH PA	D018726	Anti-Dyskinesia Agents
MeSH PA	D000978	Antiparkinson Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018765	Dopamine Uptake Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D010276	Parasympatholytics
MeSH PA	D018373	Peripheral Nervous System Agents
FDA EPC	N0000175750	Antihistamine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Postencephalitic parkinsonism	indication	19972008	DOID:14332
Parkinsonism	indication	32798002
Parkinson's disease	indication	49049000	DOID:14330
Extrapyramidal disease	indication	76349003
Arteriosclerotic Parkinsonism	indication
Urinary tract obstruction	contraindication	7163005	DOID:5200
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Severe chronic ulcerative colitis	contraindication	14311001
Disorder of autonomic nervous system	contraindication	15241006
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Shigellosis	contraindication	36188001
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Dysuria	contraindication	49650001
Paralytic ileus	contraindication	55525008	DOID:8442
Ulcerative colitis	contraindication	64766004	DOID:8577
Hiatal hernia	contraindication	84089009	DOID:12642
Open-angle glaucoma	contraindication	84494001	DOID:1067
Kidney disease	contraindication	90708001	DOID:557
Thyrotoxicosis	contraindication	90739004	DOID:7997
Myasthenia gravis	contraindication	91637004	DOID:437
Tardive dyskinesia	contraindication	102449007
Dysentery	contraindication	111939009
Gastrointestinal obstruction	contraindication	126765001
Bleeding	contraindication	131148009
Gastroesophageal reflux disease	contraindication	235595009	DOID:8534
Disease of liver	contraindication	235856003	DOID:409
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Fever	contraindication	386661006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Pseudomembranous enterocolitis	contraindication	397683000
Gastric ulcer	contraindication	397825006	DOID:10808
Disorder of coronary artery	contraindication	414024009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.86	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST	Ki	9.64	WOMBAT-PK	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.69	DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.23	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		IC50	4.62	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.86	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	6.90	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	7.50	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	5.89	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.52	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.65	DRUG MATRIX
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	8.96	WOMBAT-PK
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.93	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	ANTAGONIST	Ki	8.85	WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Ki	8.96	WOMBAT-PK
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN	ANTAGONIST	Ki	8.96	WOMBAT-PK
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN	ANTAGONIST	Ki	8.55	WOMBAT-PK
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.24	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Kd	7.25	WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.59	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	8.16	DRUG MATRIX
Sodium-dependent neutral amino acid transporter B(0)AT1	Transporter	Q695T7	S6A19_HUMAN	INHIBITOR	IC50	4.36	IUPHAR
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.39	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	6.95	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	6.85	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR		ACM2_RAT		Ki	8.59	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR		ACM1_RAT		Ki	9.23	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT		Ki	5.29	CHEMBL
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		Ki	6.93	CHEMBL

External reference:

ID	Source
D00778	KEGG_DRUG
132-17-2	SECONDARY_CAS_RN
1424	RXNORM
C0005098	UMLSCUI
CHEBI:3048	CHEBI
CXQ	PDB_CHEM_ID
CHEMBL1201203	ChEMBL_ID
CHEMBL1200383	ChEMBL_ID
DB00245	DRUGBANK_ID
7601	IUPHAR_LIGAND_ID
1201549	PUBCHEM_CID
3130	MMSL
4264	MMSL
563	MMSL
d00175	MMSL
29527005	SNOMEDCT_US
372846002	SNOMEDCT_US
77390008	SNOMEDCT_US
D001590	MESH_DESCRIPTOR_UI
292	INN_ID
4017824	VANDF
4019630	VANDF
1NHL2J4X8K	UNII
001647	NDDF
004667	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9233	INJECTION	1 mg	INTRAMUSCULAR	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9729	INJECTION	1 mg	INTRAMUSCULAR	ANDA	14 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9729	INJECTION	1 mg	INTRAMUSCULAR	ANDA	14 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2433	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2434	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2435	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2437	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2437	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2437	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2438	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2438	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2438	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2439	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2439	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2439	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8210	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8211	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8222	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8223	TABLET	1 mg	ORAL	ANDA	16 sections
benztropine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8352	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8478	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1080	TABLET	0.50 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1081	TABLET	1 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1082	TABLET	2 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6788	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6789	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6790	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7288	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7289	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7290	TABLET	2 mg	ORAL	ANDA	16 sections